Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Chronic Spontaneous Urticaria Market Value Analysis: What Growth Is Expected Over The Forecast Period?
In the historical timeframe, the market for chronic spontaneous urticaria experienced robust expansion, projected to advance from $2.23 billion in 2025 to $2.41 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.4%. This surge in the past can be ascribed to a rise in the incidence of persistent skin allergies, enhanced accessibility to newer antihistamine medications, advancements in diagnostic methodologies, an uptick in dermatology consultations, and heightened public understanding of urticaria-related ailments.
The chronic spontaneous urticaria market is poised for significant expansion, projecting a market size of $3.21 billion by 2030, driven by a CAGR of 7.4%. This projected growth throughout the forecast period is fueled by a robust pipeline of biologic drug development, escalating investments in research for autoimmune dermatological conditions, a broader application of targeted monoclonal antibody therapies, an intensified emphasis on achieving symptom-free disease management, and a greater acceptance of protracted maintenance treatment strategies. Key developments anticipated within this timeframe encompass a heightened uptake of biologic interventions for CSU, amplified utilization of sophisticated antihistamine regimens, a deepening understanding of autoimmune disease underlying mechanisms, the proliferation of individualized treatment plans, and more rigorous oversight of long-term condition control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp
Chronic Spontaneous Urticaria Market Growth Momentum: Which Factors Are Influencing Demand?
The escalating intake of alcoholic beverages is poised to be a significant catalyst for the expansion of the chronic spontaneous urticaria market. This surge in alcohol consumption can be attributed to a confluence of influences including societal customs, stress levels, marketing efforts, economic accessibility, and widespread availability. For some individuals, consuming alcohol may intensify chronic spontaneous urticaria symptoms, resulting in a greater prevalence of hives and edema. Illustrating a generational trend, a 2023 survey by the Priory Group, a UK entity offering mental health, addiction, and specialized educational services, indicated that 25% of UK residents aged 18 to 24 are now completely abstaining from alcohol, signaling a distinct move towards sobriety in younger demographics. Consequently, the upward trend in alcohol consumption is fueling the growth trajectory of the chronic spontaneous urticaria market.
Chronic Spontaneous Urticaria Market Segment Landscape: Which Areas Lead Market Development?
The chronic spontaneous urticaria market covered in this report is segmented –
1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids
2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy
3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy
Chronic Spontaneous Urticaria Market Trends Reshaping Industry Growth
Leading entities within the chronic spontaneous urticaria sector are actively innovating with next-generation Briquilimab (JSP191), aiming for superior treatment outcomes and less frequent administration. This advanced form of Briquilimab (JSP191) represents a monoclonal antibody engineered to identify and eliminate particular immune cells, specifically those expressing CD47, which are implicated in chronic spontaneous urticaria. Demonstrating this commitment, Jasper Therapeutics Inc., a US clinical-stage biotechnology firm, reported in November 2023 the enrollment of its inaugural participant in a Phase 1b/2a clinical trial evaluating Briquilimab for chronic spontaneous urticaria (CSU). This milestone marks significant progress in evaluating the safety profile and therapeutic benefits of Briquilimab, a cutting-edge monoclonal antibody targeting CD47, for managing this persistent condition characterized by hives and itching. The objective of this research is to ascertain the extent to which Briquilimab can provide relief from symptoms and enhance the overall well-being of individuals affected by CSU.
Chronic Spontaneous Urticaria Market Industry Leaders And Market Competition
Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.
Access The Complete Chronic Spontaneous Urticaria Market Report:
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report
Chronic Spontaneous Urticaria Market Regional Outlook: Where Are The Largest Opportunities Located?
North Americawas the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model